Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
US-2024041900-A1 · Feb 8, 2024 · US
Compounds as L-cystine crystallization inhibitors and uses thereof
US9040261B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9040261-B2 |
| Application number | US-201313902114-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2013 |
| Priority date | Nov 23, 2009 |
| Publication date | May 26, 2015 |
| Grant date | May 26, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R 1a , R 1b , and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for inhibiting, or slowing the growth of L-cystine crystallization comprising administering an effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate, cocrystal, or prodrug thereof, and stereoisomers, tautomers and isotopic variants thereof; and wherein A is…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/223Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9040261B2 cover?
- A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. wherein A, L, R 1a , R 1b , and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (…
- Who is the assignee on this patent?
- Ward Michael D, Rimer Jeffrey, Univ New York
- What technology area does this patent fall under?
- Primary CPC classification A61K31/223. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 26 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).